Mr. Narasimhan is a Senior Director with over 33 years of increasing responsibility and an ever broadening portfolio of international experience in the generic pharmaceutical industry.
As a member of the Executive Board and Chief Executive (Strategic Business) of ACTAVIS, one of the top-3 generic companies in the world (currently merging with Teva), he successfully worked on and implemented a “India-Euro-US” axis, establishing full product development complete with value-chain integration, regulatory, CRO and virtual low-cost manufacturing.
Until 2014 he was the Managing Director of Zenara Pharma Ltd, London/East Rutherford NJ (jointly owned with Cambrex Corporation, a NYSE listed company), first manufacturers of DC (directly compressed) Nicotine chewing gums. Zenara manufactured NICORETTE for J&J in India.
Presently he is on the board of Directors of Altima-Life Ltd, a OTC venture to establish an integrated manufacturing initiative for NRT (Nicotine Replacement Therapy) products including e-liquid and other ENDS (Electronic Nicotine Delivery system) with Strides Shasun Ltd, India . He has also advised leading Investment Bankers like 3i, Bear Stearns on the pharma sector and evaluated investment opportunities for them.